AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00076232 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acyclovir
Description: 400 mg tablet taken orally twice daily
Study NCT00076232 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Acyclovir placebo
Description: Oral tablet taken twice daily
Study NCT00658307 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: repetitive transcranial magnetic stimulation (rTMS)
Description: 1 Hz~The rTMS device is the MagPro X100 Series (produced by Magventure A/S, Farum, Denmark)
Study NCT00658307 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: repetitive transcranial magnetic stimulation (rTMS)
Description: 20Hz~The rTMS device is the MagPro X100 Series (produced by Magventure A/S, Farum, Denmark)
Study NCT00658307 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham repetitive transcranial magnetic stimulation (rTMS)
Description: The rTMS device is the MagPro X100 Series (produced by Magventure A/S, Farum, Denmark)
Study NCT03337464 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: cycling exercise
Description: 5 x 3 minute bouts of cycling exercise separated by 3 minute rest periods
Study NCT03337464 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cycling exercise
Description: 5 x 3 minute bouts of cycling exercise separated by 3 minute rest periods
Study NCT04455945 — intervention group
Intervention type: PROCEDURE
Intervention: Open Rectal cancer surgery
Description: Open sphincter preserving surgery for rectal cancer
Study NCT04455945 — intervention group
Intervention type: PROCEDURE
Intervention: Laparoscopic Rectal cancer surgery
Description: Laparoscopic sphincter preserving surgery for rectal cancer
Study NCT02303860 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORM-12741 MR A
Description: Modified release formulation of ORM-12741
Study NCT02303860 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORM-12741 MR B
Description: Modified release formulation of ORM-12741
Study NCT02303860 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORM-12741 IR
Description: Immediately release formulation of ORM-12741
Study NCT04487561 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: hemopatch
Description: The patient will be randomized after performing the lymphadenectomy, according to a table of random numbers performed in excel kuytools, then a compression bandage will be performed on all the patients and it will be controlled 24 hours postoperatively, the subsequent control will be weekly until the drain is removed. and / or the disappearance of the seroma
Study NCT04487561 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Aspirative drainage
Description: The patient will be randomized after performing the lymphadenectomy, according to a table of random numbers performed in excel kuytools, then a compression bandage will be performed on all the patients and it will be controlled 24 hours postoperatively, the subsequent control will be weekly until the drain is removed. and / or the disappearance of the seroma
Study NCT01577342 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin 0.5%
Description: 1 drop 4 times daily times 3 days post ranibizumab intravitreal injection
Study NCT02407782 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin
Description: oral ivermectin, 200μg/kg given at baseline and at day 10.
Study NCT02407782 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Permethrin
Description: topical permethrin 5% cream applied at baseline and at day 10.
Study NCT01461915 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: Nab-paclitaxel 125 mg/m2 will be administered IV over 30 minutes. Nab-paclitaxel will be administered weekly for 3 weeks followed by 1 week of rest (28-day cycle).
Study NCT03855683 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unified Protocol for The Treatment of Emotional Disorders
Description: Unified Protocol (UP) is is an 8-week intervention designed to specifically benefit individuals who report co-occurring symptoms of anxiety, stress, and mood by providing them with psychoeducation regarding (mal)adaptive emotion regulation, as well as with skills for effectively responding to stress. UP is based on a cognitive-behavioral framework and uses cognitive and behavioral therapy techniques. Each session of UP group therapy is 90 minutes in duration. Sessions themselves generally include a review of homework and previously discussed concepts, introduction of new material, and in-session discussions/activities.
Study NCT03294187 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wrist-worn wearables
Description: See arm/group description.
Study NCT03400007 — intervention group
Intervention type: DEVICE
Intervention: Dynamic floor magnetic resonance imaging
Description: Dynamic floor magnetic resonance imaging (MRI)
Study NCT03400007 — intervention group
Intervention type: DEVICE
Intervention: Colpocystodefecography
Description: Colpocystodefecography (CCD)
Study NCT03841253 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Trans-epithelial PTK
Description: The MEL 90 excimer laser will be used to ablate the corneal epithelium and stroma to a pre-defined depth, using the epithelium as a natural masking agent to smooth the stromal surface.
Study NCT03841253 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EpiMaster Application Software
Description: The EpiMaster Application Software imports epithelial thickness data and corneal front surface topography data, and uses this to calculate the refractive change that would be induced by a trans-epithelial PTK treatment.
Study NCT02502136 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: carbon dioxide insufflation during endoscopy
Description: Efficacy and safety study of carbon dioxide insufflation instead of air during sedated endoscopy
Study NCT02502136 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Room air insufflation during endoscopy (Placebo)
Description: Efficacy and safety study of carbon dioxide insufflation instead of air during sedated endoscopy
Study NCT03406390 — intervention group
Intervention type: PROCEDURE
Intervention: Pterygium surgery
Description: The patients were anesthetized with subconjunctival injection.Symblepharon was released and fibrotic tissue was extensively dissected to expose the sclera and corneal stroma. The subconjunctival fibrovascular tissue, including Tenon's capsule, were thoroughly removed using scissors from the sclera and medial rectus muscle at the area of the superior and inferior fornices and the nasal caruncle. A cryopreserved human amniotic membrane (Zhongshan Ophthalmic Center, China) was then placed on the entire exposed bare sclera with the epithelial side facing upward, and secured with 10-0 nylon sutures.
Study NCT01180959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 10 mg/kg by vein once every 2 weeks on days 1 and 15 of each cycle. The first dose of bevacizumab will be given over about 90 minutes
Study NCT01180959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: 150 mg by mouth once a day.
Study NCT04078607 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rapid Visual Information Processing task
Description: A series of numbers appeared on a computer screen at a rate of one per minute. Each participant was required to identify any series of three consecutive odd or even numbers by hitting the space bar on the keyboard. The task lasted 15 minutes and included a 1-minute practice session before food being served. Participants were instructed to eat at will while completing the computer task.
Study NCT04078607 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: None or Control condition
Description: Participant were instructed to eat at will during a 15-minute duration.
Study NCT00725972 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Augment O2 Delivery by hemodynamic protocol
Description: Hemodynamic management to a goal of O2 delivery of 600 ml/m2/min utilizing cardiac stroke volume variation with positive pressure ventilation to optimize fluid management.
Study NCT00725972 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: High Risk Surgery
Description: Patients with same characteristics as Experimental Group having same types of Surgery but no change to usual anesthetic care
Study NCT01429285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydromorphone
Description: 0.5 mg IV hydromorphone followed by an optional 0.5 mg IV dose
Study NCT01429285 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Attending administers any IV opioid in any dose he chooses
Study NCT00679406 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Behavioral Treatment for Insomnia
Description: Effective behavioral insomnia treatments are typically delivered over an 8-week period. This format may not be easily exportable to primary and community care settings where military returnees and veterans seek help. The goal here is to test the effects of a 4-week behavioral treatment that targets chronic insomnia (lasting >1 month) in service members returning from Operation Iraqi Freedom (OIF) and Operation Enduring Freedom (OEF), and who present with the typical psychiatric comorbidities associated of combat-related anxiety and mood disorders and stress reactions.
Study NCT01549951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orteronel+Prednisone
Description: Orteronel 400-mg plus prednisone 5-mg will be administered BID orally continuously throughout the treatment cycle of the study.
Study NCT00561249 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laser assisted hatching
Description: Embryos for transfer are subjected to laser assisted hatching(LAH) following the standard procedure.The LAH procedure lasts two minutes per embryo
Study NCT00624637 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: aromatherapy massage
Description: Ten minutes massage of hands, arms or feet with mandarin essential oil 1% (Citrus reticulata) or with carrier oil only
Study NCT01342497 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: isoniazide
Description: Tablets, dosing 3 times daily, 12 weeks
Study NCT01342497 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: tablets, dosing 3 times daily, 12 weeks
Study NCT01313663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pazopanib
Description: oral agent, administered at 800 mg daily (400 mg tablets x 2). Dose can be reduced, interrupted or discontinued due to adverse events or intolerance
Study NCT01313663 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pemetrexed
Description: pemetrexed IV 500 mg/m2 once every 3 weeks
Study NCT02544191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GnRHa/ hCG/ hMG
Description: GnRHa was injected subcutaneously at a dose of 3.6mg every 28 days for 5 months. After 2 months from the first GnRHa injection, all subjects were treated with hCG at a dose of 2000 IU once a week for 3 months. After 3 months from the first Goserelin injection, all subjects were treated with hMG at a dose of 150 IU every 3 days for 2 months.
Study NCT04907617 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FAW
Description: After the induction of anaesthesia, for patients assigned to groups 1 and 3, the cover of the forced-air warming device (Bair HuggerTM Warming Unit, Model 505, Augustine Medical Inc., Eden Prairie, MN, USA) will be covered over the patient, with the surgical site exposed, and the temperature adjustment of the device will be set to the maximum (43°C). Then, the temperature will be adjusted to maintain a patient temperature of at least 36.5°C. When the patient's body temperature reaches 37°C, the device will be turned off and it will be restarted at a temperature measurement of \<36.5°C.
Study NCT04907617 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Warmed fluids
Description: In patients assigned to groups 2 and 3, intraoperative IV (Automer blood/fluid warming system, Acemedikal, South Korea) and irrigation fluids (Enthermic Warming Cabinet 1002W, Poland) will be given by heating to 37°C in a thermostatically controlled heating cabinet.
Study NCT01461915 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nab paclitaxel
Description: Nab-paclitaxel 125 mg/m2 will be administered IV over 30 minutes. Nab-paclitaxel will be administered weekly for 3 weeks followed by 1 week of rest (28-day cycle).
Study NCT01461915 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Following the completion of nab-paclitaxel administration, gemcitabine IV infusion at 1000 mg/m2 will be administered over 30 minutes. Gemcitabine will be administered weekly for 3 weeks followed by 1 week of rest (28-cycle).
Study NCT01461915 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Following the completion of nab-paclitaxel administration, gemcitabine IV infusion at 1000 mg/m2 will be administered over 30 minutes. Gemcitabine will be administered weekly for 3 weeks followed by 1 week of rest (28-cycle).
Study NCT01461915 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dociparstat
Description: Following the completion of gemcitabine administration, dociparstat IV bolus at 4 mg/kg will be administered in 5 minutes immediately after completion of gemcitabine administration. Immediately following the dociparstat IV bolus administration, dociparstat 48-hour IV continuous infusion at 0.375 mg/kg/hr will be administered.
Study NCT04575311 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AB680
Description: AB680 is a Cluster of Differentiation (CD)73 Inhibitor
Study NCT04575311 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo
Study NCT01984827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: 1. a single oral dose of 400mg Moxifloxacin plus a hyper-glycaemic clamp for 4 hours~2. a single oral dose of 400mg Moxifloxacin plus C-peptide~3. a single oral dose of 400mg Moxifloxacin~4. placebo~Oral doses of placebo and moxifloxacin will be administered by a Research Physician or Pharmacy staff member between 08:00 a.m. and 10:00 a.m.
Study NCT01984827 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Moxifloxacin
Description: 1. a single oral dose of 400mg Moxifloxacin plus a hyper-glycaemic clamp for 4 hours~2. a single oral dose of 400mg Moxifloxacin plus C-peptide~3. a single oral dose of 400mg Moxifloxacin~4. placebo~Oral doses of placebo and moxifloxacin will be administered by a Research Physician or Pharmacy staff member between 08:00 a.m. and 10:00 a.m.
Study NCT01984827 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hyper-glycaemic clamp
Description: a hyper-glycaemic clamp only for 2 hours followed by a hyper-glycaemic clamp plus C-peptide for 2 hours
Study NCT04907617 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combination
Description: After the induction of anaesthesia, for patients assigned to groups 3, the cover of the forced-air warming device (Bair HuggerTM Warming Unit, Model 505, Augustine Medical Inc., Eden Prairie, MN, USA) will be covered over the patient, with the surgical site exposed, and the temperature adjustment of the device will be set to the maximum (43°C). Then, the temperature will be adjusted to maintain a patient temperature of at least 36.5°C. When the patient's body temperature reaches 37°C, the device will be turned off and it will be restarted at a temperature measurement of \<36.5°C.~In patients assigned to groups 3, intraoperative IV (Automer blood/fluid warming system, Acemedikal, South Korea) and irrigation fluids (Enthermic Warming Cabinet 1002W, Poland) will be given by heating to 37°C in a thermostatically controlled heating cabinet.
Study NCT02446756 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupuncture
Study NCT04907617 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: The patients assigned to group 4 will only receive 'routine care'. They will not be given intraoperative forced-air warming or heated IV and irrigation fluids.
Study NCT02446756 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: physiotherapy
Study NCT01171261 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Games Field Trial
Description: There were 4 arms to the intervention in the field trial of this study. Participants were randomized to one of 4 arms or exergame that were manufactured by SSD/Xavix (Shiseido Co. of Japan). Each exergame consisted of a game cartridge, the XavixPort, and game controllers (e.g., tennis racquets, boxing gloves, bowling ball, or floor mat). The XavixPort interfaces the exergame with the participant's television and contains the infrared sensors that track the movement of the game controllers. Each exergame cartridge includes multiple game modes. The four arms/exergames were: XaviX Tennis, The Jackie Chan Studio Fitness (J-MAT), XaviX Bowling, and XaviX Boxing.
Study NCT02012049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperdal OD Tab. 2mg
Description: 1 tablet Risperdal OD 2 mg administered orally.
Study NCT02386124 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: frailty evaluation
Description: assessment of mental and physical frailty before discharge from cardiac departement
Study NCT02012049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperdal Quicklet Tab. 2mg
Description: 1 tablet Risperdal Quicklet Tab. 2mg administered orally.
Study NCT01940627 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ubiquinol
Description: Ubiquinol 200mg/day (two capsules of 100 mg (Breakfast and lunch)) for 14 days
Study NCT01940627 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: placebo capsules (two capsules (Breakfast and lunch)) for 14 days
Study NCT02789592 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin PR
Description: For experimental treatment of RBD
Study NCT02789592 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonazepam
Description: For experimental treatment of RBD
Study NCT02789592 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin PR placebo
Description: Placebo pill manufactured to mask melatonin PR 2mg tablet
Study NCT02789592 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonazepam placebo
Description: Placebo pill manufactured to mask clonazepam 0.5mg tablet
Study NCT03787992 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alflutinib Mesylate (AST2818) 80mg//40 mg+ placebo
Description: The initial dose of AST2818 80 mg once daily can be reduced to 40 mg once daily under specific circumstances. A cycle of treatment is defined as 21 days of once daily treatment.~Number of Cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.
Study NCT03787992 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Gefitinib 250 mg
Description: The initial dose of Placebo Gefitinib 250 mg once daily cannot be reduced. A cycle of treatment is defined as 21 days of once daily treatment. Number of cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.
Study NCT03787992 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gefitinib 250 mg
Description: The initial dose of Gefitinib 250mg once daily cannot be reduced. A cycle of treatment is defined as 21 days of once daily treatment.~Number of Cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.
Study NCT03787992 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo AST2818 80mg//40 mg
Description: The initial dose of Placebo AST2818 80 mg once daily can be reduced to Placebo AST2818 40 mg once daily under specific circumstances. A cycle of treatment is defined as 21 days of once daily treatment. Number of cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.
Study NCT02750956 — intervention group
Intervention type: PROCEDURE
Intervention: Non-surgical periodontal treatment
Description: Non-surgical periodontal therapy is an anti-infective therapy which includes both mechanical and chemotherapeutic approaches to minimize or eliminate microbial biofilm, the primary etiology of gingivitis and periodontitis
Study NCT01229137 — intervention group
Intervention type: DEVICE
Intervention: SRD-1 conversion
Study NCT01116973 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: PICC
Description: Peripheral inserted catheter placement to take the reading
Study NCT01612208 — intervention group
Intervention type: DEVICE
Intervention: Periarticular Locking Plate (NCB, Zimmer)
Description: The proximal plate segment will be applied to the diaphysis using four 5.0 mm MotionLoc screws. The plate will not be compressed onto the femoral diaphysis to preserve periosteal perfusion and to enable controlled motion between the plate and the diaphysis. If desirable, temporary spacers of the NCB set may be used in the proximal plate segment to facilitate 1-2 mm plate elevation over the diaphysis. Only MotionLoc screws will be used for fixation of the NCB plate proximal to the fracture site.
Study NCT01612208 — intervention group
Intervention type: DEVICE
Intervention: MotionLoc Screw
Description: The NCB Polyaxial Locking Plate System is indicated for temporary internal fixation and stabilization of fractures and osteotomies of long bones. These MotionLoc screws have a reduced 3.4 mm diameter mid-shaft section to bypass the near cortex. By avoiding rigid constraint in the near cortex, the MotionLoc screw design increases the working length of the screw, allowing for elastic flexion of the screw shaft within a controlled motion envelope in the near cortex.